Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer: EuroGemDoce group results.
Scilipoti P, Longoni M, de Angelis M, Zaurito P, Massiet A, Dutto D, Soria F, Álvarez-Maestro M, Bazán AA, Pradere B, Klatte T, Contieri R, Hurle R, Krajewski W, Subiela JD, Pichler R, Szostek A, Marcq G, Elena JLR, Aranda J, Gontero P, Rouprêt M, Shariat SF, Necchi A, Montorsi F, Briganti A, Xylinas E, Moschini M; EuroGemDoce Study Group Collaborators; European Association of Urology ‐ Young Academic Urologists (EAU‐YAU); Urothelial Carcinoma Working Group.
Scilipoti P, et al. Among authors: zaurito p.
BJU Int. 2025 Jan 11. doi: 10.1111/bju.16645. Online ahead of print.
BJU Int. 2025.
PMID: 39797535